Search results
8 cze 2021 · The current recommendations address treatment with the following: 1) conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs); 2) glucocorticoids; and 3) use of these medications in certain high-risk populations.
11 lip 2018 · Overview. This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms.
8 cze 2021 · Objective To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. Methods We developed clinically relevant population, intervention, comparator, and outcomes...
Support for patients and carers in managing rheumatoid arthritis through education, self-management and the provision of information and advice. Location of review. Non-specialist referral to specialist services. Non-pharmacological treatments for managing rheumatoid arthritis, including: o podiatry o physiotherapy
10 sty 2024 · This comprehensive review explores the multifaceted landscape of rheumatoid arthritis (RA), encompassing its epidemiology, pathophysiology, clinical manifestations, diagnosis, treatment...
Treatment options for rheumatoid arthritis (RA) have expanded with availability of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).1 The updated European League Against Rheumatism (EULAR, from 2021, European Alliance of Associations for Rheumatology) recommendations for the management of RA2 focusing on ...
Rheumatoid arthritis, or RA, is a chronic (long-term) autoimmune disease involving inflammation in joints and other parts of the body. While there is no cure for RA at present, the search is ongoing and many efec-tive treatments are currently available. Inflammation in RA causes pain, stifness and swelling in and around joints.
